Motus GI: Soars as FDA approves gastrointestinal endoscopy device
30/04/2021 13:09
** Medtech co's MOTS.O shares surge 53% to $1.7 premarket,
set for their best day in 3 months
** Stock among top pct. gainers across U.S. exchanges
** Co says it has received clearance from U.S. FDA for a
version of its Pure-Vu System for gastrointestinal endoscopy
urn:newsml:reuters.com:*:nGNXbXw1gq
** The system is used in upper gastrointestinal endoscopy
procedures to remove blood, blood clots and debris in order to
provide a clear field-of-view for the endoscopist - MOTS
** Stock up ~15% this year, as of Thursday's close
(Reporting by Dania Nadeem in Bengaluru)
((Dania.Nadeem@thomsonreuters.com;))
Recent news on Motus GI Holdings
See all newsBrief: Motus GI Holdings Inc Continuing To Explore A Range Of Strategic And Financing Alternatives
Brief: Motus Gi Holdings Files Prospectus Related To Resale Of Up To 4.4 Million Shares Of Common Stock, By The Selling Stockholder
Brief: Motus GI Granted A U.S. Patent For Key Feature Embodied By The Pure-Vu System
U.S. STOCKS ON THE MOVE-Chewy, Amgen, Bluebird bio
Brief: Motus Gi Holdings Says Prices Public Offering At $1.50 Per Share